PDF(Pubmed)
Abstract：
Gastric cancer (GC) is recognized as one of the most common deadly malignancies worldwide and about 40-50% of patients present at diagnosis with an unresectable disease due to a locally advanced or already metastatic condition. Recently, therapeutic options for management of metastatic GC (mGC) have been approved allowing a potential improvement of patient cancer treatment response and also an establishment of a continuum of care for this aggressive disease. This report is the result of a literature review by an expert panel. The aim of this document is to provide evidence, wherever it is lacking, to provide expert opinion directed at strategic management of mGC, and in particular aspect at practical management where appropriate guidelines are not available. Treatment landscape with new therapeutic strategies for third line and beyond, role of imaging, prognostic factors, symptoms, and markers as well as the importance of multidisciplinary approach particularly the nutritional aspects are discussed.
摘要：
胃癌（GC）被认为是世界上最常见的致命恶性肿瘤之一，约40-50％的患者在诊断时由于局部晚期或已经转移的疾病而无法切除。最近,转移性GC(mGC)的治疗选择已经获得批准,这使得患者的癌症治疗反应有可能得到改善,并且也为这种侵袭性疾病建立了连续的治疗.本报告是专家小组文献综述的结果。这份文件的目的是提供证据，无论缺少什么，针对mGC的战略管理提供专家意见，特别是在没有适当指导方针的实际管理方面。为三线及以后提供新的治疗策略的治疗景观，成像的作用，预后因素，症状,和标记以及多学科方法的重要性，特别是营养方面的讨论。
